| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 39 | 2024 | 806 | 9.670 |
Why?
|
| Cardiovascular Diseases | 48 | 2024 | 1159 | 8.870 |
Why?
|
| Coronary Artery Disease | 32 | 2024 | 427 | 6.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 19 | 2023 | 167 | 5.670 |
Why?
|
| Anticholesteremic Agents | 12 | 2023 | 47 | 5.150 |
Why?
|
| Hyperlipoproteinemia Type II | 14 | 2023 | 20 | 5.150 |
Why?
|
| Dyslipidemias | 11 | 2024 | 59 | 4.200 |
Why?
|
| Hypercholesterolemia | 11 | 2023 | 72 | 4.200 |
Why?
|
| Lipoprotein(a) | 13 | 2023 | 25 | 4.110 |
Why?
|
| Cardiology | 12 | 2024 | 104 | 4.060 |
Why?
|
| Cholesterol, LDL | 20 | 2024 | 170 | 3.990 |
Why?
|
| Humans | 160 | 2024 | 32284 | 2.840 |
Why?
|
| Tomography, X-Ray Computed | 26 | 2020 | 906 | 2.730 |
Why?
|
| Risk Factors | 49 | 2024 | 3938 | 2.370 |
Why?
|
| Lipids | 9 | 2024 | 250 | 2.280 |
Why?
|
| Coronary Angiography | 18 | 2024 | 159 | 2.220 |
Why?
|
| Antibodies, Monoclonal | 7 | 2019 | 246 | 2.120 |
Why?
|
| Preventive Medicine | 5 | 2021 | 8 | 2.080 |
Why?
|
| Risk Assessment | 23 | 2024 | 1424 | 1.800 |
Why?
|
| Cholesterol | 10 | 2024 | 258 | 1.780 |
Why?
|
| Coronary Vessels | 10 | 2024 | 173 | 1.680 |
Why?
|
| Hypertriglyceridemia | 4 | 2022 | 9 | 1.490 |
Why?
|
| Coronary Disease | 8 | 2024 | 226 | 1.490 |
Why?
|
| Cardiovascular System | 3 | 2024 | 49 | 1.480 |
Why?
|
| Middle Aged | 65 | 2024 | 11843 | 1.360 |
Why?
|
| Myocardial Infarction | 13 | 2023 | 466 | 1.350 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2020 | 6 | 1.320 |
Why?
|
| Calcium | 9 | 2024 | 337 | 1.310 |
Why?
|
| Lipoproteins | 4 | 2022 | 92 | 1.180 |
Why?
|
| Male | 76 | 2024 | 19434 | 1.150 |
Why?
|
| Chest Pain | 10 | 2023 | 205 | 1.100 |
Why?
|
| Treatment Outcome | 18 | 2023 | 3410 | 1.090 |
Why?
|
| Female | 71 | 2024 | 19954 | 1.090 |
Why?
|
| Acute Coronary Syndrome | 9 | 2016 | 167 | 1.090 |
Why?
|
| Primary Prevention | 6 | 2023 | 55 | 1.040 |
Why?
|
| United States | 25 | 2024 | 4079 | 0.990 |
Why?
|
| Diabetes Mellitus | 7 | 2024 | 390 | 0.940 |
Why?
|
| Aged | 36 | 2024 | 10257 | 0.900 |
Why?
|
| Hyperlipidemias | 3 | 2023 | 60 | 0.890 |
Why?
|
| C-Reactive Protein | 4 | 2024 | 226 | 0.890 |
Why?
|
| Triglycerides | 5 | 2024 | 234 | 0.840 |
Why?
|
| Ketocholesterols | 1 | 2023 | 1 | 0.810 |
Why?
|
| Predictive Value of Tests | 15 | 2023 | 880 | 0.800 |
Why?
|
| Prediabetic State | 2 | 2023 | 76 | 0.770 |
Why?
|
| Adult | 36 | 2024 | 9263 | 0.770 |
Why?
|
| American Heart Association | 2 | 2020 | 92 | 0.760 |
Why?
|
| Risk Reduction Behavior | 3 | 2019 | 117 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 394 | 0.710 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 38 | 0.690 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 24 | 0.680 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 212 | 0.640 |
Why?
|
| Family Practice | 2 | 2023 | 49 | 0.630 |
Why?
|
| Apolipoproteins | 1 | 2021 | 193 | 0.600 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 110 | 0.600 |
Why?
|
| Hypertension | 4 | 2023 | 983 | 0.590 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 17 | 0.590 |
Why?
|
| Niacin | 1 | 2019 | 7 | 0.590 |
Why?
|
| Mutation | 4 | 2018 | 497 | 0.580 |
Why?
|
| Aspirin | 1 | 2019 | 59 | 0.580 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 232 | 0.570 |
Why?
|
| Drug Costs | 1 | 2019 | 46 | 0.560 |
Why?
|
| Cannabis | 1 | 2019 | 30 | 0.560 |
Why?
|
| Prospective Studies | 19 | 2023 | 2320 | 0.550 |
Why?
|
| Pancreatitis | 1 | 2018 | 20 | 0.540 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 245 | 0.530 |
Why?
|
| Inflammation | 3 | 2023 | 500 | 0.530 |
Why?
|
| Drug Resistance | 1 | 2017 | 42 | 0.530 |
Why?
|
| Wolman Disease | 1 | 2017 | 2 | 0.510 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 144 | 0.470 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 9 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 1211 | 0.460 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 96 | 0.450 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.450 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 99 | 0.440 |
Why?
|
| Prognosis | 9 | 2024 | 1529 | 0.430 |
Why?
|
| Aortic Valve Stenosis | 2 | 2023 | 40 | 0.420 |
Why?
|
| Time Factors | 7 | 2019 | 2196 | 0.400 |
Why?
|
| Blood Glucose | 3 | 2021 | 484 | 0.400 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 1485 | 0.400 |
Why?
|
| Decision Support Systems, Clinical | 5 | 2012 | 63 | 0.400 |
Why?
|
| Columbidae | 1 | 2013 | 3 | 0.400 |
Why?
|
| Pigmentation | 1 | 2013 | 6 | 0.400 |
Why?
|
| Melanins | 1 | 2013 | 7 | 0.400 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2013 | 6 | 0.400 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 40 | 0.390 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 264 | 0.390 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2010 | 24 | 0.390 |
Why?
|
| Exercise Test | 2 | 2016 | 218 | 0.390 |
Why?
|
| Cell Membrane | 1 | 2013 | 109 | 0.380 |
Why?
|
| Myocardial Revascularization | 3 | 2022 | 34 | 0.380 |
Why?
|
| Decision Making | 2 | 2022 | 190 | 0.380 |
Why?
|
| Myocardium | 4 | 2010 | 184 | 0.380 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 98 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 548 | 0.370 |
Why?
|
| Contrast Media | 10 | 2010 | 136 | 0.360 |
Why?
|
| Image Enhancement | 2 | 2009 | 66 | 0.360 |
Why?
|
| Sensitivity and Specificity | 11 | 2010 | 555 | 0.360 |
Why?
|
| Aortography | 2 | 2009 | 16 | 0.350 |
Why?
|
| Cohort Studies | 7 | 2021 | 1840 | 0.350 |
Why?
|
| Reperfusion Injury | 1 | 2011 | 60 | 0.330 |
Why?
|
| Pulmonary Veins | 2 | 2008 | 20 | 0.320 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 325 | 0.310 |
Why?
|
| Animals | 9 | 2020 | 8165 | 0.310 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 6 | 0.310 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 3896 | 0.300 |
Why?
|
| Kidney | 2 | 2023 | 520 | 0.300 |
Why?
|
| MicroRNAs | 1 | 2011 | 181 | 0.290 |
Why?
|
| Cause of Death | 3 | 2019 | 236 | 0.290 |
Why?
|
| Triiodobenzoic Acids | 7 | 2010 | 8 | 0.280 |
Why?
|
| Electrocardiography | 6 | 2016 | 624 | 0.280 |
Why?
|
| Aortic Diseases | 1 | 2009 | 59 | 0.280 |
Why?
|
| Heart Failure | 3 | 2024 | 727 | 0.280 |
Why?
|
| Early Diagnosis | 3 | 2024 | 57 | 0.270 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 51 | 0.270 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 105 | 0.270 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 180 | 0.270 |
Why?
|
| Stroke | 3 | 2023 | 691 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 821 | 0.260 |
Why?
|
| Metoprolol | 1 | 2007 | 3 | 0.260 |
Why?
|
| Registries | 6 | 2020 | 294 | 0.260 |
Why?
|
| Atrial Appendage | 1 | 2007 | 24 | 0.260 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2007 | 58 | 0.260 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3612 | 0.260 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 31 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 58 | 0.250 |
Why?
|
| Thrombosis | 1 | 2007 | 78 | 0.250 |
Why?
|
| Phenotype | 5 | 2023 | 619 | 0.250 |
Why?
|
| Acute Disease | 5 | 2018 | 253 | 0.250 |
Why?
|
| Emergency Service, Hospital | 6 | 2023 | 444 | 0.240 |
Why?
|
| Heart Diseases | 1 | 2007 | 114 | 0.240 |
Why?
|
| Coronary Circulation | 4 | 2010 | 41 | 0.230 |
Why?
|
| Heart Rate | 2 | 2007 | 364 | 0.230 |
Why?
|
| Mortality | 2 | 2024 | 122 | 0.210 |
Why?
|
| Qualitative Research | 4 | 2020 | 180 | 0.210 |
Why?
|
| Ischemia | 2 | 2023 | 115 | 0.210 |
Why?
|
| Hospitalization | 4 | 2024 | 476 | 0.210 |
Why?
|
| Oregon | 3 | 2019 | 7 | 0.200 |
Why?
|
| Sleep | 1 | 2024 | 87 | 0.200 |
Why?
|
| Dicarboxylic Acids | 1 | 2023 | 6 | 0.200 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 2238 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1436 | 0.190 |
Why?
|
| Radiographic Image Enhancement | 3 | 2007 | 30 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2023 | 72 | 0.190 |
Why?
|
| Heterozygote | 3 | 2019 | 60 | 0.190 |
Why?
|
| Fatty Acids | 1 | 2023 | 100 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 140 | 0.180 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 287 | 0.180 |
Why?
|
| Obesity | 4 | 2023 | 1108 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2022 | 85 | 0.180 |
Why?
|
| History, 20th Century | 3 | 2019 | 74 | 0.180 |
Why?
|
| Biology | 1 | 2021 | 2 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 69 | 0.170 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2010 | 38 | 0.170 |
Why?
|
| Natural History | 1 | 2021 | 2 | 0.170 |
Why?
|
| Lipid Metabolism | 2 | 2024 | 104 | 0.170 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 364 | 0.170 |
Why?
|
| Education | 1 | 2021 | 31 | 0.170 |
Why?
|
| Europe | 1 | 2021 | 82 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 773 | 0.170 |
Why?
|
| Telemedicine | 2 | 2020 | 122 | 0.170 |
Why?
|
| Mice | 3 | 2018 | 2544 | 0.170 |
Why?
|
| Diffusion of Innovation | 2 | 2019 | 33 | 0.170 |
Why?
|
| Spirituality | 1 | 2021 | 39 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2021 | 39 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2021 | 78 | 0.160 |
Why?
|
| Genome, Human | 2 | 2015 | 130 | 0.160 |
Why?
|
| Health Status Disparities | 2 | 2023 | 128 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2019 | 62 | 0.160 |
Why?
|
| Ethnic Groups | 2 | 2020 | 450 | 0.160 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 502 | 0.160 |
Why?
|
| Dementia | 1 | 2023 | 246 | 0.160 |
Why?
|
| Dairying | 1 | 2020 | 1 | 0.160 |
Why?
|
| Apolipoproteins B | 2 | 2017 | 48 | 0.160 |
Why?
|
| Young Adult | 6 | 2024 | 2652 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 293 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 27 | 0.160 |
Why?
|
| Logistic Models | 4 | 2020 | 743 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2019 | 160 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 2020 | 26 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 75 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 29 | 0.150 |
Why?
|
| Professional Role | 1 | 2019 | 21 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 47 | 0.150 |
Why?
|
| Pharmacists | 1 | 2019 | 20 | 0.150 |
Why?
|
| Life Style | 2 | 2020 | 394 | 0.150 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 543 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2010 | 168 | 0.150 |
Why?
|
| Medical Assistance | 1 | 2019 | 3 | 0.140 |
Why?
|
| Education, Medical | 1 | 2019 | 69 | 0.140 |
Why?
|
| Adolescent | 6 | 2023 | 3521 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2019 | 18 | 0.140 |
Why?
|
| Calcinosis | 3 | 2009 | 142 | 0.140 |
Why?
|
| Internet | 1 | 2020 | 202 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 305 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 276 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 95 | 0.140 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 38 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2010 | 99 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 293 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2019 | 66 | 0.140 |
Why?
|
| Angiography | 1 | 2018 | 76 | 0.140 |
Why?
|
| RNA Interference | 1 | 2018 | 77 | 0.130 |
Why?
|
| Survival Rate | 2 | 2017 | 892 | 0.130 |
Why?
|
| Curriculum | 1 | 2019 | 203 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 76 | 0.130 |
Why?
|
| Receptors, LDL | 1 | 2018 | 55 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2017 | 455 | 0.130 |
Why?
|
| Hypobetalipoproteinemias | 1 | 2017 | 1 | 0.130 |
Why?
|
| Angiopoietins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 336 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 1052 | 0.130 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 23 | 0.130 |
Why?
|
| Tomography, Spiral Computed | 2 | 2008 | 19 | 0.130 |
Why?
|
| Cholesterol, HDL | 3 | 2024 | 181 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 151 | 0.130 |
Why?
|
| Mass Screening | 1 | 2019 | 256 | 0.130 |
Why?
|
| Social Class | 1 | 2017 | 90 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 179 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 317 | 0.130 |
Why?
|
| Income | 1 | 2017 | 66 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 29 | 0.130 |
Why?
|
| Ankle Brachial Index | 1 | 2017 | 38 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2019 | 232 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2019 | 211 | 0.130 |
Why?
|
| Artifacts | 2 | 2007 | 45 | 0.130 |
Why?
|
| Base Sequence | 2 | 2015 | 256 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 172 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 368 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.120 |
Why?
|
| Vaccination | 1 | 2018 | 156 | 0.120 |
Why?
|
| Skin Diseases, Genetic | 1 | 2016 | 4 | 0.120 |
Why?
|
| Vascular Malformations | 1 | 2016 | 11 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2016 | 9 | 0.120 |
Why?
|
| Emergency Medical Services | 2 | 2009 | 183 | 0.120 |
Why?
|
| Retinal Vessels | 1 | 2016 | 25 | 0.120 |
Why?
|
| Genomic Structural Variation | 1 | 2015 | 2 | 0.120 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 851 | 0.120 |
Why?
|
| Arteries | 1 | 2016 | 75 | 0.120 |
Why?
|
| Quality of Life | 1 | 2021 | 971 | 0.120 |
Why?
|
| Coronary Stenosis | 4 | 2010 | 28 | 0.120 |
Why?
|
| Skull Fractures | 1 | 2015 | 16 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 491 | 0.110 |
Why?
|
| Electronic Health Records | 3 | 2011 | 179 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 312 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 188 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 19 | 0.110 |
Why?
|
| Aortic Valve | 2 | 2023 | 58 | 0.110 |
Why?
|
| Spinal Fractures | 1 | 2015 | 37 | 0.110 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 49 | 0.110 |
Why?
|
| Prevalence | 3 | 2024 | 960 | 0.110 |
Why?
|
| Joint Instability | 1 | 2016 | 87 | 0.110 |
Why?
|
| Heart | 3 | 2024 | 177 | 0.110 |
Why?
|
| Comorbidity | 3 | 2023 | 563 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2015 | 252 | 0.110 |
Why?
|
| Triage | 3 | 2010 | 68 | 0.110 |
Why?
|
| Gadolinium DTPA | 3 | 2010 | 15 | 0.100 |
Why?
|
| Feathers | 1 | 2013 | 1 | 0.100 |
Why?
|
| Open Reading Frames | 1 | 2013 | 21 | 0.100 |
Why?
|
| Principal Component Analysis | 2 | 2011 | 67 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2013 | 58 | 0.100 |
Why?
|
| Haplotypes | 1 | 2013 | 213 | 0.100 |
Why?
|
| Protestantism | 2 | 2023 | 6 | 0.100 |
Why?
|
| Florida | 2 | 2023 | 41 | 0.100 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 293 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 45 | 0.090 |
Why?
|
| Alleles | 1 | 2013 | 250 | 0.090 |
Why?
|
| Algorithms | 1 | 2015 | 537 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2008 | 410 | 0.090 |
Why?
|
| Apolipoprotein C-III | 2 | 2022 | 6 | 0.090 |
Why?
|
| Echocardiography | 3 | 2008 | 190 | 0.090 |
Why?
|
| Age Factors | 3 | 2024 | 1179 | 0.090 |
Why?
|
| Sex Factors | 3 | 2020 | 656 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 98 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2011 | 9 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 58 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 110 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 650 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2011 | 56 | 0.080 |
Why?
|
| Public Health | 2 | 2024 | 91 | 0.080 |
Why?
|
| Disease Progression | 2 | 2024 | 590 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2023 | 197 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 37 | 0.080 |
Why?
|
| Radiation Protection | 1 | 2011 | 11 | 0.080 |
Why?
|
| Community Health Services | 1 | 2011 | 47 | 0.080 |
Why?
|
| Myocardial Reperfusion | 2 | 2008 | 9 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2011 | 171 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2009 | 192 | 0.080 |
Why?
|
| Commerce | 1 | 2011 | 69 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 83 | 0.080 |
Why?
|
| Radiometry | 1 | 2011 | 52 | 0.080 |
Why?
|
| Tissue Survival | 1 | 2010 | 13 | 0.080 |
Why?
|
| Tunica Media | 1 | 2010 | 39 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2010 | 76 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 48 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2010 | 33 | 0.080 |
Why?
|
| Incidence | 3 | 2024 | 1244 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2008 | 20 | 0.080 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2009 | 11 | 0.080 |
Why?
|
| Heart Ventricles | 2 | 2008 | 146 | 0.070 |
Why?
|
| Smegmamorpha | 1 | 2009 | 1 | 0.070 |
Why?
|
| Sex Chromosomes | 1 | 2009 | 4 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 236 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 478 | 0.070 |
Why?
|
| Angina Pectoris | 1 | 2009 | 20 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 776 | 0.070 |
Why?
|
| Collateral Circulation | 1 | 2008 | 10 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 25 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2009 | 77 | 0.070 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2008 | 14 | 0.070 |
Why?
|
| Length of Stay | 2 | 2023 | 321 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 81 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2008 | 13 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 39 | 0.070 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2007 | 1 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2008 | 113 | 0.070 |
Why?
|
| Stroke Volume | 3 | 2024 | 417 | 0.060 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2007 | 26 | 0.060 |
Why?
|
| Aorta | 1 | 2007 | 120 | 0.060 |
Why?
|
| California | 2 | 2021 | 61 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 55 | 0.060 |
Why?
|
| Tomography, Optical Coherence | 1 | 2006 | 45 | 0.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2006 | 46 | 0.060 |
Why?
|
| Age Distribution | 2 | 2021 | 194 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 126 | 0.060 |
Why?
|
| Exercise | 2 | 2021 | 605 | 0.060 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2005 | 1 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 368 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 160 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 56 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 345 | 0.050 |
Why?
|
| Iran | 1 | 2023 | 5 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 755 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2023 | 75 | 0.050 |
Why?
|
| Asia | 1 | 2023 | 19 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2023 | 74 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2024 | 127 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 191 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 86 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 169 | 0.050 |
Why?
|
| African Americans | 2 | 2020 | 1335 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 302 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 33 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 47 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2022 | 25 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 14 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2021 | 21 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 863 | 0.040 |
Why?
|
| New Mexico | 1 | 2021 | 6 | 0.040 |
Why?
|
| Arizona | 1 | 2021 | 7 | 0.040 |
Why?
|
| Texas | 1 | 2021 | 41 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 47 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2022 | 184 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 111 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 83 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 174 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2023 | 318 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 218 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 30 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 44 | 0.040 |
Why?
|
| Animal Welfare | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cattle Diseases | 1 | 2020 | 3 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 252 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2020 | 8 | 0.040 |
Why?
|
| New York | 1 | 2020 | 21 | 0.040 |
Why?
|
| Employment | 1 | 2020 | 45 | 0.040 |
Why?
|
| Cattle | 1 | 2020 | 118 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 217 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 32 | 0.040 |
Why?
|
| North Carolina | 1 | 2023 | 1299 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 168 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 72 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 99 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2023 | 866 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 34 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 287 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 187 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 98 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 95 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 167 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 566 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 132 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 709 | 0.030 |
Why?
|
| North America | 1 | 2017 | 31 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 136 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 83 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 760 | 0.030 |
Why?
|
| Asian Americans | 1 | 2017 | 92 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 133 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 297 | 0.030 |
Why?
|
| Patient Selection | 2 | 2011 | 272 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2010 | 858 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Singapore | 1 | 2016 | 7 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2008 | 93 | 0.030 |
Why?
|
| Expert Systems | 1 | 2016 | 4 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 426 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 2016 | 27 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 34 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2016 | 74 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 131 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 243 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 52 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2020 | 772 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 16 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 109 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 247 | 0.030 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 30 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 110 | 0.030 |
Why?
|
| Software | 1 | 2015 | 125 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 86 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 80 | 0.030 |
Why?
|
| Physicians | 1 | 2016 | 163 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2446 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 674 | 0.030 |
Why?
|
| Institutional Management Teams | 1 | 2012 | 2 | 0.020 |
Why?
|
| Systems Analysis | 1 | 2012 | 3 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 8 | 0.020 |
Why?
|
| Inservice Training | 1 | 2012 | 12 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2012 | 11 | 0.020 |
Why?
|
| Research Personnel | 1 | 2012 | 22 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2012 | 91 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 42 | 0.020 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2011 | 6 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 12 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 33 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2011 | 90 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 181 | 0.020 |
Why?
|
| Homocysteine | 1 | 2010 | 15 | 0.020 |
Why?
|
| Body Composition | 1 | 2012 | 327 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 90 | 0.020 |
Why?
|
| Rest | 1 | 2010 | 49 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 77 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 273 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2009 | 21 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 141 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 42 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 75 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 3 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 394 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 154 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 66 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 478 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 96 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 59 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 75 | 0.010 |
Why?
|
| Cadaver | 1 | 2006 | 151 | 0.010 |
Why?
|
| Rubidium Radioisotopes | 1 | 2005 | 7 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 49 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2005 | 31 | 0.010 |
Why?
|
| Leukocytes | 1 | 2005 | 59 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 121 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 167 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 706 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 240 | 0.010 |
Why?
|